International Medical Case Reports Journal (Feb 2020)
Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis®)
Abstract
Soraya Alessandra Horowitz, 1 Nadyr P Damasceno, 1 Eduardo F Damasceno 2 1Department of Ophthalmology, Hospital Naval Marcilio Dias, Rio de Janeiro, Brazil; 2Department of Ophthalmology, Universidade Federal Fluminense, Niteroi, BrazilCorrespondence: Soraya Alessandra Horowitz; Nadyr P DamascenoDepartment of Ophthalmology, Hospital Naval Marcílio Dias (HNMD), 185 Rua Cesar Zama, Lins, Rio de Janeiro, BrazilEmail [email protected]; [email protected]: To report a treatment of radiation retinopathy in a patient exposed to ionizing radiation for a period of 2 years. A 26-year-old female patient with no comorbidities diagnosed with myelodysplasia confirmed by bone marrow biopsy. She presented a complaint of bilateral progressive visual acuity reduction. At the ophthalmologic examination, she presented alterations suggestive of radiation retinopathy as well as macular thickness to optical coherence tomography (OCT) of over 500 μm. The patient underwent intravitreal injection (0.05 mL) of ranibizumab (Lucentis®) monthly in both eyes and follow-up through visual acuity and OCT examination. She presented reduction of macular edema as well as a slight improvement of visual acuity. In this case, the treatment of radiation retinopathy with intravitreal injection of ranibizumab (Lucentis) was relatively useful, with a slight improvement of visual acuity, due to the regression of macular edema, not being curative.Keywords: retinopathy abnormalities, retina/radiation effects, intravitreal injection, angiogenesis inhibitors/therapeutic use, macular edema, improvement of visual acuity
